F-star Therapeutics announces CFIUS clearance for proposed acquisition by invoX

F-star Therapeutics announced that the Committee on Foreign Investment in the United States has cleared the previously announced all-cash acquisition of the Company by invoX Pharma Limited. The CFIUS clearance satisfies the Foreign Investment Condition of the ongoing tender offer, and is the final required regulatory approval needed to complete the proposed merger. As described below, the parties expect to complete the merger promptly following the successful completion of the ongoing tender offer. Specifically, the Offer is scheduled to expire on March 8, 2023 at 5 p.m., Eastern Time. Subject to the tendering of shares of F-star common stock representing greater than 50% of the issued and outstanding shares and the satisfaction of customary conditions, the parties expect to complete the merger promptly following this tender expiry. Previously, shares of common stock representing nearly 70% of the issued and outstanding shares had been validly tendered as of the prior expiration dates.